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radiation therapy preceded or not by radical
prostatectomy, concurrent intensified-dose
docetaxel and long-term androgen deprivation
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Background: The optimal management of high-risk prostate cancer remains uncertain. In this study we assessed
the safety and efficacy of a novel multimodal treatment paradigm for high-risk prostate cancer.
Methods: This was a prospective phase II trial including 35 patients with newly diagnosed high-risk localized or
locally advanced prostate cancer treated with high-dose intensity-modulated radiation therapy preceded or not by
radical prostatectomy, concurrent intensified-dose docetaxel-based chemotherapy and long-term androgen
deprivation therapy. Primary endpoint was acute and late toxicity evaluated with the Common Terminology Criteria
for Adverse Events version 3.0. Secondary endpoint was biochemical and clinical recurrence-free survival explored
with the Kaplan-Meier method.
Results: Acute gastro-intestinal and genito-urinary toxicity was grade 2 in 23% and 20% of patients, and grade 3 in
9% and 3% of patients, respectively. Acute blood/bone marrow toxicity was grade 2 in 20% of patients. No acute
grade ≥4 toxicity was observed. Late gastro-intestinal and genito-urinary toxicity was grade 2 in 9% of patients
each. No late grade ≥3 toxicity was observed. Median follow-up was 63 months (interquartile range 31–79).
Actuarial 5-year biochemical and clinical recurrence-free survival rate was 55% (95% confidence interval, 35-75%)
and 70% (95% confidence interval, 52-88%), respectively.
Conclusions: In our phase II trial testing a novel multimodal treatment paradigm for high-risk prostate cancer,
toxicity was acceptably low and mid-term oncological outcome was good. This treatment paradigm, thus, may
warrant further evaluation in phase III randomized trials.
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Table 2 Acute adverse events recorded during concurrent
high-dose intensity-modulated radiation therapy and
docetaxel-based chemotherapy: allergy/immunology
Grade Allergic reactions Highest
Cohort 1
1 1 1
2 0 0
3 0 0
Cohort 2
1 0 0
2 1 1
3 2 2
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Depending on the definition, high-risk localized or lo-
cally advanced prostate cancer (PCa) accounts for 15-
40% of newly diagnosed cases [1,2]. Despite advances in
patient selection and primary/adjuvant therapies, disease
recurrence remains substantial, affecting >50% of pa-
tients within 10 years after treatment [3,4].
In the absence of adequately conducted randomized
trials, optimal treatment remains controversial. External
beam radiation therapy (EBRT) with long-term androgen
deprivation therapy (ADT) has long been considered the
standard of care over other modalities [5,6]. The survival
benefit of long-term ADT combined with EBRT vs.
EBRT alone has recently been confirmed in a meta-
analysis [7]. Over the past decade, however, there has
been a surge in the utilization of radical prostatectomy
(RP) as primary treatment in selected patients, followed
by EBRT in case of adverse pathological features [5,6]. It
is currently accepted that a combined modality-regimen
should be pursued in clinical trials, although sequence,
timing and intensity of the single treatments are still
under scrutiny [8].Table 1 Clinical and tumor characteristics of patients with
high-risk localized or locally advanced prostate cancer
enrolled in our phase II trial
Variable Cohort 1 (n=18) Cohort 2 (n=17)
Age, years, median (IQR) 59 (56–63) 69 (67–73)
Serum PSA level, ng/ml, median
(IQR)
17 (8–26) 18 (9–28)
Clinical T stage, n T2 6 5
T3 12 11
T4 0 1
Clinical N stage, n N0 16 15
N+ 2 2
Biopsy Gleason score, n 6 3 2
3+4 1 2
4+3 4 7
8-10 9 6
Pathological T stage*, n T2c 2 NA
T3a 3
T3b 11
T4 2
Positive lymph node status, n 4 NA
Positive surgical margins, n 8 NA
Pathological Gleason score, n 8 5 NA
9 13
Follow up, months, median (IQR) 61 (45–80) 63 (26–77)
IQR = interquartile range; NA = not applicable; PSA = prostate specific antigen;
*according to the 2002 TNM classification.Docetaxel is an active agent in the treatment of PCa
but, until recently, its role has been limited to patients
with metastatic castration-resistant disease [9,10]. How-
ever, in order to treat micrometastatic disease, an earlier
use of chemotherapy within the curative treatment set-
ting may be beneficial. Docetaxel is also known as a
radiosensitizer, and has been shown to improve local
control in combination with EBRT in the treatment of
lung, head/neck and cervical cancers [11,12]. Further-
more, recent evidence suggests that a positive inter-
action effect exists also between docetaxel and ADT
[13]. All these premises have made docetaxel a suitable
agent to integrate into multimodal treatment paradigms
for high-risk PCa.
Few studies have reported on the safe use and efficacy
of docetaxel at a weekly dose of 20 mg/m2 in combin-
ation with conventional EBRT in hormone-naïve or ab-
lated high-risk PCa [14-16]. Very little, however, is
known about the effect of docetaxel administered con-
currently with state-of-the-art high-dose EBRT, e.g. en-
abled by intensity-modulated radiation therapy (IMRT),
and long-term ADT.
In a phase II trial, we evaluated the safety and efficacy of
a novel multimodal treatment paradigm for high-risk PCa
including high-dose IMRT preceded or not by RP with con-
current intensified-dose docetaxel-based chemotherapy and
long-term ADT.
Methods
Study population
Eligible subjects were men aged ≥18 years with histologi-
cally confirmed PCa and high-risk localized (PSA level
≥20 ng/ml or clinical stage T2c or Gleason score ≥8) or
locally advanced (clinical stage T3 or N+, any PSA level,
any Gleason score) disease. All patients had abdominal com-
puted tomography, chest X-ray and bone scan excluding dis-
tant metastases. Exclusion criteria were: Eastern Cooperative
Oncology Group performance status >1; hematological
abnormalities (absolute neutrophil count <1500/mm3,
hemoglobin <8.0 g/dl, platelets <105/mm3); liver function
tests abnormalities (total bilirubin >1.2 mg/dl, alanine and
aspartate transaminase >1.5× the upper normal limit,
Table 3 Acute adverse events recorded during concurrent high-dose intensity-modulated radiation therapy and
docetaxel-based chemotherapy: blood/bone marrow
Grade Anemia Leucopenia Neutropenia Thrombocytopenia Highest
Cohort 1
1 5 6 3 1 6
2 1 3 0 0 3
3 0 1 0 0 1
Cohort 2
1 6 5 2 1 5
2 2 4 1 0 4
3 0 0 0 0 0
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http://www.ro-journal.com/content/9/1/24alkaline phosphatase >2.5× the upper normal limit); renal
function tests abnormalities (creatinine >1.5× the upper nor-
mal limit); myocardial infarction or unstable angina within 1
year prior to study entry; congestive heart failure (New York
Heart Association Class ≥2); uncontrolled chronic disease;
severe infection; peripheral neuropathy; prior malignancy
(except for non-melanoma skin cancer) within the last 5
years before study entry; prior pelvic external beam radiation
therapy; prior chemotherapy; prior prostate surgery; prior
treatment for prostate cancer.
The protocol was approved by the local ethics com-
mittee of the National Cancer Institute Aviano, and the
study was conducted according to the Declaration of
Helsinki and European Good Clinical Practice require-
ments. Written informed consent was obtained at study
entry.Study design and treatments
Patients were offered one of two multimodal therapy
strategies depending on their age at PCa diagnosis. Pa-
tients aged ≤65 years were preferentially offered initial
open non-nerve-sparing RP with extended pelvic lymph
node dissection (PLND) according to a previously re-
ported, anatomically defined template [17], adjuvant
EBRT within 3–6 months postoperatively with concur-
rent docetaxel and long-term ADT (cohort 1). Older pa-
tients were preferentially offered primary EBRT with
concurrent docetaxel and long-term ADT (cohort 2).
Surgery was performed at two centres (Padua and
Pordenone).Table 4 Acute adverse events recorded during concurrent
high-dose intensity-modulated radiation therapy and
docetaxel-based chemotherapy: constitutional symptoms
Grade Fatigue Fever Hot flashes Highest
Cohort 1
1 2 2 2 4
2 1 0 2 2
3 0 0 0 0
Cohort 2
1 1 1 2 3
2 2 1 1 3
3 0 0 0 0All patients were treated with IMRT in Aviano. A 4- to
6-field technique with 15- to 18-MV photon beams was
used. No image-guided radiation therapy (IGRT) was used.
In patients of cohort 1, clinical target volume (CTV)
included the area from the level of the caudal remnant
of the vas deferens, which was intraoperatively marked
with clips, to 10 mm inferior to the vesico-urethral anas-
tomosis, from the posterior aspect of the pubis to the
anterior rectal wall, and between the medial aspects of
each obturator internus muscle. Planning target volume
(PTV) consisted of CTV plus a 5-mm margin in all di-
rections except posteriorly, where a 3-mm margin was
set. No radiation to the pelvis was given. A total dose of
70 Gy in 35 fractions was prescribed. Dose constraints
for organs at risk were: a) bladder: V65 Gy ≤50%, V40
Gy ≤70%; b) rectum: V65 Gy ≤35%, V40 Gy ≤55%; c)
femoral heads: V50 Gy ≤10%.
In patients of cohort 2, CTV1 included the pelvic area
encompassing external iliac, obturator, internal iliac and
lower common iliac lymph node chains bilaterally, from
the inferior margin of L5 to the inferior margin of the
inferior pubic branch, and CTV2 included prostate and
seminal vesicles. PTV1 consisted of CTV1 plus a 10-mm
margin in all directions, and PTV2 consisted of CTV2
plus a 10-mm margin in all directions, except poster-
iorly, where a 6-mm margin was set. A total dose of
80 Gy in 40 fractions was prescribed in three phases: i)
first phase: 26 Gy in 13 fractions to PTV1 + PTV2; ii)
second phase: 30 Gy in 15 fractions to PTV2; iii) third
phase: 24 Gy in 12 fractions to PTV1 + PTV2. Dose
constraints for organs at risk were: a) bladder: V80Table 5 Acute adverse events recorded during concurrent
high-dose intensity-modulated radiation therapy and
docetaxel-based chemotherapy: dermatology/skin
Grade Rash/dermatitis Highest
Cohort 1
1 2 2
2 0 0
3 0 0
Cohort 2
1 1 1
2 0 0
3 0 0
Table 6 Acute adverse events recorded during concurrent high-dose intensity-modulated radiation therapy and
docetaxel-based chemotherapy: gastrointestinal symptoms
Grade Nausea/vomiting Diarrhea Gastritis Proctitis Hematochezia Highest
Cohort 1
1 3 8 2 2 2 8
2 2 3 0 1 0 3
3 0 1 0 1 0 2
Cohort 2
1 2 7 2 2 1 7
2 3 4 1 1 1 5
3 0 1 0 0 0 1
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http://www.ro-journal.com/content/9/1/24Gy ≤15%, V70 Gy ≤35%, V50 Gy ≤60%; b) rectum: V70
Gy ≤20%, V60 Gy ≤35%, V50 Gy ≤50%; c) femoral heads:
V50 Gy ≤5%.
Docetaxel was administered starting on the same week
as IMRT in a standard 1-hour intravenous weekly dose
(30 mg if body surface area <1.8 m2 and 40 mg if body
surface area ≥1.8 m2) for 7 and 8 weeks in patients of
cohort 1 and 2, respectively. Premedication with intra-
venous methylprednisolone, chlorphenamine and ondan-
setron was given prior to each docetaxel infusion.
ADT, consisting of an injection of a 3-monthly LHRH-
agonist, was started either immediately after surgery in
cases of pathologically proven seminal vesicle and/or
lymph node invasion or 1 to 2 months before IMRT in
patients in cohort 1, and 2 to 3 months before treatment
in patients of cohort 2. No antiandrogens were given.
ADT was prescribed for 24 months in all patients.Follow-up
During concurrent IMRT/docetaxel physical examin-
ation, complete blood count and toxicity assessment
were obtained weekly. After completion, patients were
followed with physical examination, urinalysis, serum
PSA, liver and renal function tests 3-monthly for the
first 2 years, 6-monthly for the following 3 years, and an-
nually thereafter. Follow-up began either on the date of
RP (cohort 1) or the date of IMRT completion (cohort
2), and continued until last observation or death.Table 7 Acute adverse events recorded during concurrent hig
docetaxel-based chemotherapy: genitourinary symptoms
Grade
Frequency/urgency Dysuria
B A A* B A A* B
Cohort 1
1 3 6 3 1 2 1 3
2 1 3 2 0 0 0 3
3 0 0 0 0 0 0 0
Cohort 2
1 3 7 4 2 2 1 0
2 3 5 2 0 1 1 0
3 0 0 0 0 0 0 0
B = baseline (before concurrent intensity-modulated radiation therapy and docetax
events of higher grade than baseline.Study endpoints
Primary endpoint was safety. Complications after RP
were assigned according to the modified Clavien classifi-
cation system [18]. Toxicity related to concurrent
IMRT/docetaxel was scored according to the National
Cancer Institute Common Terminology Criteria for Ad-
verse Events version 3.0 [19]. Baseline gastro-intestinal
(GI) and genito-urinary (GU) symptoms before IMRT/
docetaxel initiation were investigated. Acute toxicity was
defined as occurring during and until 3 months after
IMRT/docetaxel, while late toxicity as occurring after 3
months until the time of administration of salvage treat-
ment. Similarly to previous investigators [20], toxicity
was defined as increase over baseline value for each
symptom. All adverse events occurring in a given patient
at any follow-up visit were recorded, but only the high-
est toxicity grade per patient was counted as event when
calculating the toxicity rate. To explore toxicity change
with time, the incidence of late toxicity at the last
follow-up visit was also reported.
Secondary endpoint was efficacy. Biochemical recur-
rence was defined as an increase in PSA level above
0.2 ng/ml [5] for patients treated with RP or an increase
of 2 ng/ml above nadir [21] for patients treated with pri-
mary IMRT. Clinical recurrence was defined as local or
regional (pelvic lymph nodes) tumour growth, or distant
metastases (including retroperitoneal lymph nodes). Bio-
chemical recurrence-free survival (BRFS) and clinical
recurrence-free survival (CRFS) were calculated fromh-dose intensity-modulated radiation therapy and
Incontinence Retention Hematuria Highest
A A* B A A* B A A* A A*
4 1 0 2 2 0 1 1 9 5
4 1 0 0 0 0 0 0 7 3
0 0 0 0 0 0 0 0 0 0
2 2 3 5 2 0 2 2 8 6
1 1 2 3 1 0 1 1 8 4
0 0 0 1 1 0 0 0 1 1
el-based chemotherapy); A = all acute adverse events; A* = acute adverse
Table 8 Late adverse events recorded after concurrent high-dose intensity-modulated radiation therapy and
docetaxel-based chemotherapy: constitutional symptoms
Grade Fatigue Hot flashes Highest during follow-up Highest at last follow-up
Cohort 1
1 1 3 3 2
2 1 0 1 1
3 0 0 0 0
Cohort 2
1 2 2 3 2
2 1 1 1 0
3 0 0 0 0
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chemical and clinical recurrence, respectively, or death
from any cause.
Statistical analyses
A Simon’s two-stage design was used to calculate the op-
timal sample size [22]. The trial was designed to test an
acute grade ≥3 toxicity rate of ≤5%, considered as ac-
ceptable to design a phase III trial, against an acute
grade ≥3 toxicity rate of ≥20%, considered as unaccept-
able, with an 85% power and a 5% significance level.
Stopping rule was grade ≥3 toxicity in ≥4 patients during
the first stage (17 patients) or in ≥3 patients in the sec-
ond stage (18 patients). Interim analyses in the second
stage were planned every 6 patients.
Continuous variables were non-normally distributed
according to Kolmogorov-Smirnov test, and are reported
as median with interquartile range (IQR). All analyses
were based on intention to treat. Kaplan-Meier estimates
were used to explore BRFS and CRFS. Analyses were
performed with SAS Enterprise Guide v4.3 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Between January 2005 and March 2012, 35 men, 18 in
cohort 1 and 17 in cohort 2, were enrolled. All patients
had complete baseline and follow-up data and were
available for the present analysis. Median age was 64
years (IQR 58-69). Median follow-up was 63 months
(IQR 31-79). Details are reported in Table 1.
All patients in cohort 1 and 14 in cohort 2 completed
IMRT to the prescribed dose. Three patients in cohort 2Table 9 Late adverse events recorded after concurrent high-d
docetaxel-based chemotherapy: gastrointestinal symptoms
Grade Diarrhea Gastritis Proctitis Hemat
Cohort 1
1 1 1 1
2 0 0 1
3 0 0 0
Cohort 2
1 1 0 2
2 1 0 1
3 0 0 0received 78 Gy because of non-compliance. Eight and 27
patients received 30 mg and 40 mg docetaxel, respect-
ively. Chemotherapy was interrupted in two patients in
cohort 2 on initiation of the 2nd cycle because of grade 3
allergic reaction. All patients completed ADT for the
prescribed duration.
Safety
In the first stage, three patients had grade ≥3 toxicity,
hence the trial was continued. In the second stage, two
further patients had grade ≥3 toxicity, hence the trial
was completed.
Perioperative complications after RP and extended
PLND were prolonged (>14 days) lymphorrhea (n = 1)
(grade I “d”), pelvic hematoma (n = 1) and urinary tract
infection (n = 2) (both grade II).
Before IMRT/docetaxel, GI symptoms were absent,
while GU symptoms were present in 11 patients, five in
cohort 1 and six in cohort 2.
Acute adverse events were common, but most of
grade ≤2. All grade 3 events resolved by the time of
the subsequent chemotherapy cycle. No grade 4 ad-
verse events were observed. GI and GU symptoms
prevailed. Acute GI and GU toxicity was grade 2 in
23% and 20% of patients, and grade 3 in 9% and 3%
of patients, respectively. Acute blood/bone marrow
toxicity was grade 2 in 20% of patients. All details are
reported in Tables 2,3,4,5,6,7.
The rate of late adverse events was low and no grade ≥3
toxicity was observed. Late GI and GU toxicity was grade 2
in 9% of patients each. At the last follow-up visit, grade 2
GI and GU toxicity was present in 0% and 6% of pa-ose intensity-modulated radiation therapy and
ochezia Highest during follow-up Highest at last follow-up
1 3 1
1 1 0
0 0 0
2 3 2
0 2 0
0 0 0
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obstruction or urethral stricture. Details are reported in
Tables 8,9,10.
Efficacy
One month after RP 12 patients had an undetectable
(<0.01 ng/ml) PSA level. Three months after IMRT/do-
cetaxel completion, all patients of cohort 1 had an un-
detectable PSA level, and all patients of cohort 2
achieved a post-treatment PSA level of ≤1 ng/ml, includ-
ing 9 patients who achieved an undetectable level.
Fourteen patients (40%), eight in cohort 1 and six in
cohort 2, had biochemical recurrence. Actuarial 5-year
BRFS rate was 55% (95% CI, 35-75%), 46% (95% CI, 19-
73%) for cohort 1 and 68% (95% CI, 42-95%) for cohort
2 (Figure 1a).
Ten patients (29%), five in each cohort, had clinical re-
currence. Local recurrence, regional recurrence and dis-
tant metastases were detected in three, two and three
patients, respectively. The two remaining patients had
concomitant local and regional recurrence, and regional
recurrence and distant metastases. Actuarial 5-year
CRFS rate was 70% (95% CI, 52-88%), 74% (95% CI, 51-
96%) for cohort 1 and 65% (95% CI, 36-94%) for cohort
2 (Figure 1b).
Salvage treatment was high-intensity focused ultra-
sound prostate ablation (n = 1), helical tomotherapy
(n = 2), ADT (n = 7), chemotherapy (n = 3), or supportive
care (n = 1). Four patients (all in cohort 1) died, two of
PCa and two of cardiovascular disease in absence of dis-
ease recurrence and ADT.
Discussion
In the present study, we explored safety and efficacy of a
novel multimodal treatment regimen for high-risk PCa
based on high-dose IMRT preceded or not by RP, con-
current intensified-dose docetaxel and long-term ADT.
Acute toxicity was common but mostly of mild to mod-
erate severity, late toxicity rate was low with no severe
adverse events, and mid-term oncological outcome was
good.Table 10 Late adverse events recorded after concurrent high-
docetaxel-based chemotherapy: genitourinary symptoms
Grade Frequency/urgency Dysuria Incontinence Retentio
L L* L L* L L* L L
Cohort 1
1 3 1 1 0 2 1 0 0
2 0 1 0 0 2 1 0 0
3 0 0 0 0 0 0 0 0
Cohort 2
1 3 1 1 0 1 1 2 1
2 2 1 0 0 1 1 2 1
3 0 0 0 0 0 0 0 0
L = all late adverse events; L* = adverse events of higher grade than baseline.Six trials have explored the role of concurrent EBRT and
taxane-based chemotherapy in patients with high-risk PCa
[14-16,23-25] (Table 11). Direct comparison between these
and the present trial is hampered by differences in study de-
sign, type of EBRT and chemotherapeutic agent used, ADT
duration, toxicity assessment and follow-up length. Notably,
all previous studies but one [25] applied conventional-dose
EBRT only (using either three-dimensional conformal radi-
ation therapy [3D-CRT] or IMRT), which is now consid-
ered suboptimal. A meta-analysis, in fact, concluded that
high-dose EBRT is associated with a significant improve-
ment in BRFS compared to conventional-dose EBRT, re-
gardless of PCa risk category [26]. Additionally, IMRT has
been shown to be able to deliver a higher dose to the pros-
tate while reducing GI and GU toxicity compared to 3D-
CRT [27], thus it is currently regarded the most effective
form of EBRT.
The only available trial in which high-dose IMRT was
used [25] was a phase I trial, where 18 patients with
high-risk PCa were treated with high-dose IMRT, con-
current docetaxel at increasing doses and long-term
ADT. Only three patients received a dose of 20 mg/m2
and none experienced ≥ grade 3 adverse events. In this
context, our phase II trial, which used high-dose IMRT,
has particular value. In our study, toxicity was common,
but was mostly grade ≤2. Most symptoms were of the
GI and GU tract. A strength of our analysis is the de-
tailed reporting of both acute and late toxicity, which in-
cluded the evaluation of baseline symptoms.
Our study included also high-risk PCa patients with prior
RP, who may exhibit a different acute and late toxicity pro-
file from their surgery-naïve counterparts, in spite of the
lower radiation dose delivered. To the best of our know-
ledge, only one study [24] explored a similar treatment
paradigm also in RP patients. Fifty-nine men with high-risk
PCa, including 30 who had undergone RP, were treated
with 3D-CRT and concurrent weekly paclitaxel. Although
the trial was not designed to test differences between post-
RP and non-post-RP patients, overall grade 3 GI and GU
toxicity was more common in post-RP patients, whereas es-
timates of biochemical and clinical recurrence were similar.dose intensity-modulated radiation therapy and
n Hematuria Highest during follow-up Highest at last follow-up
* L L* L L* L L*
1 1 5 3 2 1
1 1 2 1 2 1
0 0 0 0 0 0
1 1 6 3 4 2
1 1 3 2 2 1
0 0 0 0 0 0
Figure 1 Kaplan-Meier estimates of a) biochemical recurrence-free survival and b) clinical recurrence-free survival.
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treatment regimen including high-dose IMRT and doce-
taxel, but was similarly not equipped for this scope, al-
though both functional and oncological outcome were
apparently comparable in the two cohorts.
Over the past few years, there has been an increasing
interest towards higher-dose taxane-based chemother-
apy. In the ongoing phase III Radiation Therapy Oncol-
ogy Group-0521 trial (ClinicalTrials.gov, NCT00288080),
which is evaluating whether adjuvant docetaxel to EBRT
with ADT provides a survival advantage over EBRT withADT alone in high-risk localized PCa, a high dosage of
75 mg/m2 every 3 weeks for 6 weeks is used. In our
study, an intensified dosage of docetaxel was used com-
pared to previous trials. This was decided in an attempt
to further improve the oncological outcome, given the
tolerability of the 20 mg/m2 dose established in the piv-
otal trial by Kumar et al. [14]. The above-mentioned lim-
itations notwithstanding, toxicity profile in the present
and previous trials is apparently comparable.
Concerning the oncological outcome, our results are
comparable to those of the two trials with the longest
Table 11 Prospective clinical trials evaluating concurrent external beam radiation therapy and taxane-based chemotherapy for high-risk prostate cancer
Study Design N
patients
EBRT
technique
EBRT
dosage (Gy)
Taxane
drug
Taxane dosage
(mg/m2)
ADT duration
(months)
Toxicity scoring
system
Highest acute
GU toxicity §
Highest acute
GI toxicity §
Highest late
toxicity §
Biochemical
recurrence
Follow-up,
median
(months)
Kumar
[14]
Phase
I
22 3D-CRT 70.2 Docetaxel 5 (n=3), 8 (n=3), None CTC v2.0,
RTOG †
Grade 2 Grade 3 Urinary 5/8 8
12 (n=3),
16 (n=5),
Frequency/
urgency
Diarrhea (n=2) Retention
(n=1)
20 (n=6),
25(n=2)
(n=8)
Sanfilippo
[23]
Phase
I/II
22 3D-CRT 63 (n=3),
66.6
Paclitaxel 30 9 CTC v2.0 Grade 2 Grade 3 Grade 1 6/22 38
(n=7), 70.2
(n=4),
Frequency/
urgency
Diarrhea (n=4) Frequency
73.8 (n=8) (n=4) (n=2)
Perrotti
[15]
Phase
I/II
20 IMRT 72 Docetaxel 20 None CTC, Grade 2 Grade 2 none 3/20 11.7
RTOG † Frequency
(n=7)
Diarrhea (n=8)
Bolla [16] Phase
II
50 3D-CRT
(n=45),
70 Docetaxel 20 <36 (n=6), CTC v2.0, Grade 3 Grade 4 Grade 3 NR ‡ 54
IMRT
(n=5)
36 (n=43), RTOG † Dysuria (n=2) Proctitis (n=1) Proctitis
(n=1)
>36 (n=1)
Hussain
[24]
Phase
I
59 3D-CRT 70.2 (n=29), Paclitaxel 40 (n=10), 4 (n=29), CTC v2.0 Grade 2 Grade 3 NA 13/29,
11/30*
76.3, 74.9*
64.8 (n=30)* 50 (n=31), 24 (n=30) Frequency/
urgency/
Diarrhea (n=9)
60 (n=18) Incontinence
(n=5)
Chen [25] Phase
I
18 IMRT 78 Docetaxel 10 (n=9), 24 CTCAE v3.0 Grade 2 Grade 3 NA 3/18 26
15 (n=6), Frequency
(n=2)
Diarrhea (n=2)
20 (n=3)
Present
series
Phase
II
35 IMRT 80 (n=17), Docetaxel 30 mg (n=8), 24 CTCAE v3.0 Grade 3 Grade 3 Grade 2
urinary
6/17, 8/18* 63
70 (n=18)* 40 mg (n=27) Urinary
retention
Diarrhea Retention
(n=1) (n=2) (n=2)
3D-CRT = three-dimensional conformal radiation therapy; ADT = androgen deprivation therapy; CTC = Common Toxicity Criteria of the National Cancer Institute; CTCAE = Common Terminology Criteria for Adverse
Events of the National Cancer Institute; EBRT = external beam radiation therapy; GI = gastrointestinal symptoms; GU = genitourinary symptoms; IMRT = intensity-modulated radiation therapy; NA = not assessed;
NR = not reported; RTOG = Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicity criteria.
*Patients with previous radical prostatectomy; † late toxicity; ‡ clinical disease-free survival was 66.72% at 5 years; § when two or more events, only the most common was reported.
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http://www.ro-journal.com/content/9/1/24follow-up, where a 41% biochemical recurrence rate [25]
and a 67% 5-year CRFS [16] were observed. One may argue
that our mid-term biochemical outcome is similar to that
reported in previous studies using conventional-dose EBRT
with long-term ADT [28]. Nonetheless, we believe that our
results do justify the conduct of a phase III trial where
high-risk patients are randomized between high-dose IMRT
with ADT plus concurrent docetaxel and high-dose IMRT
with ADT alone, with appropriate oncological outcomes as
the primary endpoint. In fact, our treatment paradigm
might prove beneficial if hard endpoints (e.g. metastasis-
free and cancer-free survival) and a sufficiently long-term
follow-up are considered. On the other hand, a recent study
on ultra-high-dose (86.4 Gy) IMRT for localized PCa [29]
has reported higher BRFS rates (67.9%) in high-risk patients
at a similar follow-up (5.5 years). One may speculate that
IMRT delivered at this very high dose can achieve a better
improvement, at least, in local control, than docetaxel-
based chemo-radiation. However, whether concurrent do-
cetaxel confers a true benefit has to be seen in the pattern
of clinical recurrence, where the incidence of regional and
distant metastases is expected to be lower. Future research
in this area is eagerly awaited.
To the best of our knowledge, two phase II/III trials
and one phase III trial testing EBRT with ADT plus
concurrent docetaxel vs EBRT with ADT alone in high-
risk PCa are currently recruiting patients (ClinicalTrials.
gov, NCT00116142, NCT01603420 and NCT01811810).
However, in none of these trials the experimental arm
entails a combination of high-dose IMRT, intensified-
dosage docetaxel-based chemotherapy and long-term
ADT, such as in our trial.
Our study is not devoid of limitations. First, no control
group was available. Second, toxicity was graded accord-
ing to a physician-based assessment and health-related
quality of life was not assessed. Third, IGRT may have
contributed to improve the toxicity profile. Fourth, the
choice between RP and RT was based on an arbitrary
age cut-off with its inherent limitations. Fifth, as per our
trial protocol post-RP EBRT was given to patients with
either extracapsular disease, seminal vesicle invasion or
positive surgical margins, which are all established risk
factors for local recurrence. The latest results of a large
randomized trial on adjuvant EBRT vs observation fol-
lowing RP for high-risk PCa [28] showed that patients
with positive surgical margins benefit most from adju-
vant EBRT in subgroup analyses. Our study started in
2005, i.e. at a time when mature data on post-RP EBRT
outcomes were not available. However, even currently,
the impact of positive surgical margins on biochemical
and clinical recurrence remains under debate. In another
similar randomized trial [30], surgical margin status was
not an independent predictor of biochemical outcome.
Finally, irradiation to pelvic lymph nodes in addition tothe prostate in cN0 high-risk PCa, as in our cohort 2 pa-
tients, remains controversial. One option would be a sta-
ging PLND, whereby pN0 patients might be spared
irradiation and pN1 patients might benefit from irradi-
ation with long-term ADT [5].
Conclusions
In a phase II trial including patients with high-risk local-
ized or locally advanced PCa we showed acceptably low
toxicity and good efficacy of a multimodal treatment in-
cluding high-dose IMRT preceded or not by RP, concur-
rent intensified-dose docetaxel and long-term ADT.
Thus, this treatment paradigm may warrant further
evaluation in phase III randomized trials.
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